Actively Recruiting
Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.
Led by Centre Hospitalier Régional d'Orléans · Updated on 2025-12-30
100
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a comparative, prospective, non-interventional study to evaluate immune response in patients with chronic kidney disease. The primary objective is to define immunodeficiency (phenotype and function of T cells) in patients with end-stage kidney disease. The second objective is to provide an in-vitro proof-of-concept of T-cell engineering in the context of end-stage kidney disease. The study population was patients with chronic kidney disease.
CONDITIONS
Official Title
Assessment of T-cell Response and In-vitro Proof-of-concept of T-cell Engineering in Chronic ESKD Patients.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 years or older
- Informed consent given without objection to participation
You will not qualify if you...
- Chronic progressive infections
- Prior organ transplantation, including bone marrow transplantation
- Treatment with immunosuppressive agents (such as Rituximab, Eculizumab, Tacrolimus, Ciclosporin, Cellcept, or Imurel) within 2 years before inclusion
- Participant under guardianship, curatorship, or deprived of liberty
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center Hospitalier Universitaire d'Orléans
Orléans, France, 45067
Actively Recruiting
Research Team
M
Manon DEKEYSER, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here